Forus and the American Gastroenterological Association (AGA) have formed a strategic partnership to improve access to medications for people living with digestive diseases. The collaboration combines AGA’s clinical expertise and evidence-based guidelines with Forus’ AI-powered medication access platform, which automates processes such as prior authorizations, appeals, pharmacy routing and financial assistance. Together, the organizations aim to reduce delays that often prevent patients from receiving prescribed therapies, even when strong clinical evidence supports their use.
Forus’ platform is designed to streamline the path from prescription to treatment by navigating complex insurance and pharmacy requirements at no cost to patients or healthcare providers. Through the partnership, AGA will gain greater visibility into the real-world barriers patients encounter when accessing medications, helping the organization strengthen its advocacy efforts, inform policy discussions and provide additional resources for gastroenterologists. The collaboration seeks to bridge the gap between clinical recommendations and actual patient access to care.
The organizations plan to expand the initiative over time by developing shared insights, educational resources and data-driven strategies for the gastrointestinal community. More broadly, the partnership highlights the growing role of AI in addressing administrative obstacles within healthcare, demonstrating how medical societies and technology companies can work together to improve treatment access, reduce friction in the medication approval process and support better outcomes for patients with chronic digestive conditions.
Click here to read the original news story.
